Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
BMS gains boost for Sotyktu with FDA nod to treat psoriatic arthritis
Bristol Myers Squibb’s psoriasis drug Sotyktu has received FDA approval to treat active psoriatic arthritis in adults, making it the first selective allosteric TYK2 inhibitor approved for this indication. This expansion allows BMS to reach more patients and is backed by trial data showing significant improvement in disease activity. The company aims for Sotyktu to reach $4 billion in peak sales, although it is still behind Opdualag and Camzyos in current sales.